Linzagolix clinical trials
Also written KLH-2109.
How each study uses linzagolix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the linzagolix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 1
Kissei Pharmaceutical Co., Ltd. (11) · ObsEva SA (3) · Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test linzagolix, phase 3 first.
- Nov 2027A Clinical Study of KLH-2109 in Patients With EndometriosisPhase 3 · Kissei Pharmaceutical Co., Ltd.
- Dec 2026Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)Not applicable · Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)
Studies
Open first, then newest update. How each study uses linzagolix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)Not yet recruitingNot applicableCentro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)NCT07732348Written as Linzagolix
- A Clinical Study of KLH-2109 in Patients With EndometriosisActive, not recruitingPhase 3Kissei Pharmaceutical Co., Ltd.NCT07015268Written as KLH-2109
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and PainCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT05445167Written as KLH-2109
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)CompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT04335591Written as 75 mg linzagolix tablet
- Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.CompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT03992846Written as 75 mg linzagolix tablet
- A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated PainTerminatedPhase 3Kissei Pharmaceutical Co., Ltd.NCT03986944Written as 75 mg linzagolix tablet
- Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated PainTerminatedPhase 3Kissei Pharmaceutical Co., Ltd.NCT04372121Written as 75 mg linzagolix tablet
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With MenorrhagiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT05440383Written as KLH-2109
- A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With EndometriosisCompletedPhase 2ObsEva SANCT02778399Written as OBE2109
- Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal FunctionCompletedPhase 1ObsEva SANCT03961932Written as Linzagolix
- Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic FunctionCompletedPhase 1ObsEva SANCT03962049Written as Linzagolix
- Late Phase II Clinical Study of KLH-2109 in Patients With EndometriosisCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT02778919Written as KLH-2109
- A Phase II Randomized Open Label Study of KLH-2109 in Patients With EndometriosisCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT01629420Written as KLH-2109
- A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)CompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT01533532Written as KLH-2109
- A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)CompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT01395940Written as KLH-2109
Given beside what is tested · 2 — linzagolix is usual care or a partner of the new treatment
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedPhase 3ObsEva SANCT03070899Written as OBE2109
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedPhase 3ObsEva SANCT03070951Written as OBE2109
Codes
What other systems call linzagolix · ClinicalTrials.gg INT001614
- MeSH (NLM) C000716911linzagolixConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7CDW97HUEXLINZAGOLIXConfirmed FDA, NLM
- RxNorm 2621019One source FDA
- NCI Thesaurus C148479LinzagolixOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716911 | linzagolix | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7CDW97HUEX | LINZAGOLIX | Confirmed FDA, NLM |
| RxNorm | 2621019 | — | One source FDA |
| NCI Thesaurus | C148479 | Linzagolix | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.